These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 17062919

  • 1. Effects of valsartan and indapamide on plasma cytokines in essential hypertension.
    Xie QY, Wang YJ, Sun ZL, Yang TL.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2006 Oct; 31(5):629-34. PubMed ID: 17062919
    [Abstract] [Full Text] [Related]

  • 2. Effects of valsartan with or without benazepril on blood pressure, angiotensin II, and endoxin in patients with essential hypertension.
    Ke YS, Tao YY, Yang H, Yu GH.
    Acta Pharmacol Sin; 2003 Apr; 24(4):337-41. PubMed ID: 12676074
    [Abstract] [Full Text] [Related]

  • 3. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus.
    Nomura S, Shouzu A, Omoto S, Nishikawa M, Fukuhara S, Iwasaka T.
    Thromb Res; 2006 Apr; 117(4):385-92. PubMed ID: 15896827
    [Abstract] [Full Text] [Related]

  • 4. Ambulatory blood pressure-lowering effects of valsartan and enalapril after a missed dose in previously untreated patients with hypertension: a prospective, randomized, open-label, blinded end-point trial.
    Hermida RC, Ayala DE, Khder Y, Calvo C.
    Clin Ther; 2008 Jan; 30(1):108-20. PubMed ID: 18343247
    [Abstract] [Full Text] [Related]

  • 5. Kinetics of chemokines in acute myocardial infarction.
    Kobusiak-Prokopowicz M, Orzeszko J, Mazur G, Mysiak A, Orda A, Mazurek W.
    Kardiol Pol; 2005 Apr; 62(4):301-14; discussion 315-6. PubMed ID: 15928736
    [Abstract] [Full Text] [Related]

  • 6. Efficacy and safety of valsartan, an angiotensin II receptor antagonist, in hypertension after renal transplantation: a randomized multicenter study.
    Andrés A, Morales E, Morales JM, Bosch I, Campo C, Ruilope LM, Valsartan in Renal Transplantation Group.
    Transplant Proc; 2006 Oct; 38(8):2419-23. PubMed ID: 17097955
    [Abstract] [Full Text] [Related]

  • 7. [Effect of valsartan on postprandial plasma inflammatory factors in patients with essential hypertension].
    Liu L, Zhao SP, Zhou HN, Xu DY, Li JX.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2008 Sep; 33(9):809-13. PubMed ID: 18812659
    [Abstract] [Full Text] [Related]

  • 8. [The relationship between the gene polymorphism of TGF-beta1 and early renal injury in patients with essential hypertension, and the effect of the gene polymorphism of TGF- beta1 on the individual treatment with valsartan].
    Zhao C, Wang YY, Xiao ZX, Wang YP, Zhang QY.
    Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2007 Aug; 24(4):428-31. PubMed ID: 17680535
    [Abstract] [Full Text] [Related]

  • 9. Valsartan reduces interleukin-1beta secretion by peripheral blood mononuclear cells in patients with essential hypertension.
    Li QZ, Deng Q, Li JQ, Yi GH, Zhao SP.
    Clin Chim Acta; 2005 May; 355(1-2):131-6. PubMed ID: 15820487
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Reduction of QTc dispersion by the angiotensin II receptor blocker valsartan may be related to its anti-oxidative stress effect in patients with essential hypertension.
    Miyajima K, Minatoguchi S, Ito Y, Hukunishi M, Matsuno Y, Kakami M, Kawasaki M, Nishigaki K, Takemura G, Fujiwara H.
    Hypertens Res; 2007 Apr; 30(4):307-13. PubMed ID: 17541209
    [Abstract] [Full Text] [Related]

  • 12. Effects of valsartan alone versus valsartan/simvastatin combination on ambulatory blood pressure, C-reactive protein, lipoproteins, and monocyte chemoattractant protein-1 in patients with hyperlipidemia and hypertension.
    Rajagopalan S, Zannad F, Radauceanu A, Glazer R, Jia Y, Prescott MF, Kariisa M, Pitt B.
    Am J Cardiol; 2007 Jul 15; 100(2):222-6. PubMed ID: 17631074
    [Abstract] [Full Text] [Related]

  • 13. Effects of valsartan and nifedipine coat-core on systemic arterial stiffness in hypertensive patients.
    Munakata M, Nagasaki A, Nunokawa T, Sakuma T, Kato H, Yoshinaga K, Toyota T.
    Am J Hypertens; 2004 Nov 15; 17(11 Pt 1):1050-5. PubMed ID: 15533733
    [Abstract] [Full Text] [Related]

  • 14. Efficacy and tolerability of combination therapy with valsartan/hydrochlorothiazide in the initial treatment of severe hypertension.
    Calhoun DA, Glazer RD, Pettyjohn FS, Coenen PD, Zhao Y, Grosso A.
    Curr Med Res Opin; 2008 Aug 15; 24(8):2303-11. PubMed ID: 18593517
    [Abstract] [Full Text] [Related]

  • 15. Comparison of the effects of valsartan and felodipine on plasma leptin and insulin sensitivity in hypertensive obese patients.
    Fogari R, Derosa G, Zoppi A, Rinaldi A, Lazzari P, Fogari E, Mugellini A, Preti P.
    Hypertens Res; 2005 Mar 15; 28(3):209-14. PubMed ID: 16097363
    [Abstract] [Full Text] [Related]

  • 16. Impact of supportive measures on drug adherence in patients with essential hypertension treated with valsartan: the randomized, open-label, parallel group study VALIDATE.
    Düsing R, Handrock R, Klebs S, Tousset E, Vrijens B.
    J Hypertens; 2009 Apr 15; 27(4):894-901. PubMed ID: 19300114
    [Abstract] [Full Text] [Related]

  • 17. Effects of the angiotensin II type 1 receptor antagonist valsartan on the expression of superoxide dismutase in hypertensive patients.
    Yang HY, Kao PF, Chen TH, Tomlinson B, Ko WC, Chan P.
    J Clin Pharmacol; 2007 Mar 15; 47(3):397-403. PubMed ID: 17322151
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Selective angiotensin receptor antagonism with valsartan decreases arterial stiffness independently of blood pressure lowering in hypertensive patients.
    Nakamura T, Fujii S, Hoshino J, Saito Y, Mizuno H, Saito Y, Kurabayashi M.
    Hypertens Res; 2005 Dec 15; 28(12):937-43. PubMed ID: 16671331
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.